ArticleFrontiers in pharmacology2025
Integrative multi-omics and experimental analyses implicate PTK2 as a lorazepam-associated biomarker and potential therapeutic target in ovarian cancer.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer remains one of the most lethal gynecologic malignancies, characterized by high recurrence rates and chemoresistance. Recent advances suggest that neuroactive drugs such as lorazepam may exert off-target molecular effects beyond the central nervous system. However, their pharmacological relevance in tumor biology remains largely unexplored. This study aimed to identify and validate shared molecular targets of lorazepam and ovarian cancer, uncovering novel biomarkers and therapeutic mechanisms. Methods: Potential lorazepam targets were retrieved from the CTD, STITCH, and SwissTargetPrediction databases and cross-referenced with ovarian cancer-related genes from GeneCards. Bioinformatic analyses were conducted, including target screening, protein-protein interaction network construction, Lasso-Cox modeling, and functional enrichment. We further performed immune infiltration profiling, single-cell and spatial transcriptomics analyses, followed by experimental validation using qPCR, CCK-8, colony formation, wound-healing, and flow cytometry assays. Results: Fifty-one overlapping genes were identified between lorazepam and ovarian cancer, with PTK2 emerging as a central hub gene. PTK2 overexpression was significantly associated with poor prognosis, enhanced immune activation, stromal remodeling, and metabolic reprogramming. Spatial transcriptomics revealed PTK2 enrichment in malignant and fibroblast-rich regions. Functional assays confirmed that stable PTK2 knockdown inhibited proliferation, colony formation, and migration while promoting apoptosis in ovarian cancer cells. Conclusion: Our findings suggest that PTK2 may act as a putative oncogenic mediator and potential pharmacological link between lorazepam signaling and ovarian cancer progression. PTK2 functions as a biomarker and druggable target that integrates tumor growth, immune modulation, and metabolic adaptation. Targeting PTK2 may provide a promising therapeutic strategy for precision oncology and rational drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.